HopeStage
Back to all studies
CompletedNCT05905367

Fentanyl induction strategy for people receiving opioid care

About this titleRead the official source — NCT05905367
Medication studyAges 19+CanadaAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 19 years.

Listed locations
VancouverSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 29, 2024
Recruitment status
Completed
Enrollment listed in the registry
48
Sponsor
Pouya Azar
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Canada
Age range
Over 19 Years
Official registry ID
NCT05905367
Official title
Show the full official title

Rapid IV Symptom-inhibited Fentanyl Induction (SIFI) to Facilitate Rotation Onto Oral Opioid Agonist Therapy (OAT)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Vancouver

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pouya Azar.

Did this study involve medication?

Yes. The study involved medication, including Fentanyl, Methadone and Slow-release oral morphine.

Who was this study for?

Listed age limits: from 19 years.

Want to explore more studies?

Explore studies